
Xsolla SPAC 1
98
Recent news items are primarily market and sector-related and do not directly pertain to Xsolla SPAC 1’s business operations or developments.
- Thyssenkrupp Nucera won a hydrogen project in Spain, reflecting activity in the energy sector [N1].
- Natural gas prices gained due to attacks on key energy infrastructure in Iran [N2].
- CervoMed narrowed its cash runway as it prepares for multiple clinical milestones in 2026 [N3].
- HelloFresh reported a narrowed net loss for FY25 but warned on FY26 revenues and orders [N4].
- Ascendis Pharma reported positive Phase 2 trial results for TransCon HGH in Turner Syndrome [N5].
- KKR formed a $310 million partnership with PMI Electro to boost electric transport in India [N6].
- Hongkong and Shanghai Hotels swung to a FY25 profit [N7].
- Frontera Energy’s Q4 loss widened due to impairment charges and weak net sales [N8].
Xsolla SPAC 1 is a Cayman Islands-incorporated special purpose acquisition company that completed its IPO in January 2026, raising $200 million through the issuance of units consisting of Class A ordinary shares and redeemable warrants. The company’s shares trade on Nasdaq under the ticker XSLL. As a SPAC, its primary business model involves raising capital through the IPO to pursue a business combination or acquisition. The company reported a strong liquidity position as of June 30, 2026, with a current ratio of 4.55 and net income of approximately $1.66 million for the quarter, reflecting financial activity post-IPO. Risk factors disclosed in the IPO prospectus remain unchanged as of the latest quarterly filing.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The company’s successful IPO and strong liquidity position provide a solid foundation for pursuing a business combination. The unchanged risk factors suggest stability in the regulatory and operational environment. The structure of units with warrants offers potential upside participation for investors post-acquisition.
As a SPAC, the company faces risks related to identifying and completing a suitable business combination within the required timeframe. The absence of disclosed operating revenues or detailed business operations increases uncertainty. Market conditions and regulatory changes could impact the company’s ability to execute its acquisition strategy.
As a SPAC, Xsolla SPAC 1’s moat is primarily based on its capital-raising capability and management’s ability to identify and complete a value-accretive business combination. The company itself does not operate a traditional business with products or services but serves as a vehicle for acquisition, which limits traditional competitive advantages or moats.
• Business Combination Risk: The company must complete a business combination within a specified timeframe or return capital to shareholders, which may limit strategic flexibility.
• Regulatory and Market Risks: Changes in securities regulations or adverse market conditions could affect the company’s ability to complete a business combination or impact shareholder value.
• Limited Operating History: As a SPAC, the company has no operating business, which creates uncertainty regarding future performance and value creation.
Business trends: The company is positioned as a capital-raising vehicle seeking a business combination, with stable risk disclosures and strong liquidity as of mid-2026.
Execution milestones: Completion of a suitable business combination within the regulatory timeframe remains the key milestone.
Key risks: The primary risks include the ability to identify and close an acquisition, regulatory changes, and market conditions impacting SPAC performance.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Xsolla SPAC 1 is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands.
- The company completed its initial public offering (IPO) on January 30, 2026, issuing 20,000,000 units at $10.00 per unit, raising gross proceeds of $200 million.
- Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant exercisable for one Class A ordinary share at $11.50 per share.
- Simultaneously with the IPO, the company completed a private placement of 400,000 units to Xsolla SPAC I LLC at $10.00 per unit, raising $4 million.
- The company’s Class A ordinary shares trade on the Nasdaq Stock Market under the ticker XSLL.
- As of June 30, 2026, the company reported current assets of $1,844,089 and current liabilities of $405,098, resulting in a current ratio of 4.55.
- The company reported net income of $1,655,116 for the quarter ended June 30, 2026.
- The company is classified as an emerging growth company and has not elected to use the extended transition period for new accounting standards.
- Risk factors disclosed in the company’s IPO prospectus remain unchanged as of the latest quarterly report.
- The company’s financial figures are summarized from the latest available SEC filings and are provided for informational purposes only, not financial advice.
Generated 2026-08-15
- S1 | 2026-03-31 | 10-K
- S2 | 2026-08-14 | 10-Q
- N1 | 2026-03-18 | www.nasdaq.com | Thyssenkrupp Nucera Wins Hydrogen Project In Spain | https://www.nasdaq.com/articles/thyssenkrupp-nucera-wins-hydrogen-project-spain
- N2 | 2026-03-18 | www.nasdaq.com | Nat-Gas Prices Gain as Iran Attacks Key Energy Infrastructure | https://www.nasdaq.com/articles/nat-gas-prices-gain-iran-attacks-key-energy-infrastructure
- N3 | 2026-03-18 | www.nasdaq.com | CervoMed Narrows Cash Runway As It Prepares For Multiple 2026 Clinical Milestones | https://www.nasdaq.com/articles/cervomed-narrows-cash-runway-it-prepares-multiple-2026-clinical-milestones
- N4 | 2026-03-18 | www.nasdaq.com | HelloFresh FY25 Net Loss Narrows, Revenues & Orders Down; Warns On FY26 | https://www.nasdaq.com/articles/hellofresh-fy25-net-loss-narrows-revenues-orders-down-warns-fy26
- N5 | 2026-03-18 | www.nasdaq.com | Ascendis Pharma Reports Positive Results From Phase 2 Trial For TransCon HGH In Turner Syndrome | https://www.nasdaq.com/articles/ascendis-pharma-reports-positive-results-phase-2-trial-transcon-hgh-turner-syndrome
- N6 | 2026-03-18 | www.nasdaq.com | KKR Forms $310 Mln Partnership With PMI Electro To Boost Electric Transport In India | https://www.nasdaq.com/articles/kkr-forms-310-mln-partnership-pmi-electro-boost-electric-transport-india
- N7 | 2026-03-18 | www.nasdaq.com | Hongkong And Shanghai Hotels Swings To FY25 Profit | https://www.nasdaq.com/articles/hongkong-and-shanghai-hotels-swings-fy25-profit
- N8 | 2026-03-18 | www.nasdaq.com | Frontera Energy Q4 Loss Widens On Impairment Charges, Weak Net Sales | https://www.nasdaq.com/articles/frontera-energy-q4-loss-widens-impairment-charges-weak-net-sales
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


